ATE251161T1 - Triazolo(4,5-d)pyrimidin-derivate als antithrombotische mittel - Google Patents

Triazolo(4,5-d)pyrimidin-derivate als antithrombotische mittel

Info

Publication number
ATE251161T1
ATE251161T1 AT98934107T AT98934107T ATE251161T1 AT E251161 T1 ATE251161 T1 AT E251161T1 AT 98934107 T AT98934107 T AT 98934107T AT 98934107 T AT98934107 T AT 98934107T AT E251161 T1 ATE251161 T1 AT E251161T1
Authority
AT
Austria
Prior art keywords
antithrbotic
triazolo
agents
pyrimidine derivatives
pyrimidine
Prior art date
Application number
AT98934107T
Other languages
English (en)
Inventor
Simon Guile
Anthony Ingall
Brian Springthorpe
Paul Willis
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663042&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE251161(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9702773A external-priority patent/SE9702773D0/xx
Priority claimed from SE9702775A external-priority patent/SE9702775D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE251161T1 publication Critical patent/ATE251161T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
AT98934107T 1997-07-22 1998-07-15 Triazolo(4,5-d)pyrimidin-derivate als antithrombotische mittel ATE251161T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9702773A SE9702773D0 (sv) 1997-07-22 1997-07-22 Novel compounds
SE9702775A SE9702775D0 (sv) 1997-07-22 1997-07-22 Novel compounds
PCT/SE1998/001393 WO1999005143A1 (en) 1997-07-22 1998-07-15 Novel compounds

Publications (1)

Publication Number Publication Date
ATE251161T1 true ATE251161T1 (de) 2003-10-15

Family

ID=26663042

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98934107T ATE251161T1 (de) 1997-07-22 1998-07-15 Triazolo(4,5-d)pyrimidin-derivate als antithrombotische mittel

Country Status (31)

Country Link
EP (1) EP0996621B1 (de)
JP (1) JP4187406B2 (de)
KR (2) KR20050084540A (de)
CN (1) CN1154650C (de)
AR (2) AR017014A1 (de)
AT (1) ATE251161T1 (de)
AU (1) AU745381B2 (de)
BR (1) BR9810802B1 (de)
CA (1) CA2296665C (de)
CZ (1) CZ302629B6 (de)
DE (1) DE69818668T2 (de)
DK (1) DK0996621T3 (de)
EE (1) EE04193B1 (de)
EG (1) EG24412A (de)
ES (1) ES2207846T3 (de)
HK (1) HK1026421A1 (de)
HU (1) HU230074B1 (de)
IL (2) IL133959A0 (de)
IS (1) IS2236B (de)
MY (1) MY123196A (de)
NO (1) NO315854B1 (de)
NZ (1) NZ502381A (de)
PL (1) PL200325B1 (de)
PT (1) PT996621E (de)
RU (1) RU2225407C2 (de)
SA (1) SA98190487B1 (de)
SK (1) SK284199B6 (de)
TR (1) TR200000197T2 (de)
TW (1) TW530058B (de)
UA (1) UA66801C2 (de)
WO (1) WO1999005143A1 (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9903290D0 (sv) 1999-09-15 1999-09-15 Astra Pharma Prod Novel compounds
SE9904129D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
SE9904128D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
GB0013487D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Novel process
GB0013407D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
GB0013488D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
TWI290549B (en) * 2000-06-02 2007-12-01 Astrazeneca Ab Process for the preparation of cyclopropyl carboxylic acid ester and derivatives
IT1317049B1 (it) 2000-06-23 2003-05-26 Sigma Tau Ind Farmaceuti Composti utili per la preparazione di medicamenti ad attivita'inibitrice della fosfodiesterasi iv.
SE0004099D0 (sv) * 2000-11-09 2000-11-09 Astrazeneca Ab Novel compounds
SE0004098D0 (sv) 2000-11-09 2000-11-09 Astrazeneca Ab Novel compounds
GB0219746D0 (en) * 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
US7504497B2 (en) 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7368438B2 (en) 2003-10-21 2008-05-06 Inspire Pharmaceuticals, Inc. Non-nucleotide compositions and method for inhibiting platelet aggregation
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
SE0401001D0 (sv) 2004-03-31 2004-03-31 Astrazeneca Ab Chemical process
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
GB0615620D0 (en) 2006-08-05 2006-09-13 Astrazeneca Ab A process for the preparation of optically active intermediates
US7566722B2 (en) 2006-10-31 2009-07-28 Janssen Pharmaceutica, N.V. Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
ES2558843T3 (es) 2008-09-09 2016-02-09 Astrazeneca Ab Procedimiento para preparar [1S-[1-alfa,2-alfa,3-beta(1S*,2R*),5-beta]]-3-[7-[2-(3,4-difluorofenil)-ciclopropilamino]-5-(propiltio)-3H-1,2,3-triazolo[4,5-d]pirimidin-3-il]-5-(2-hidroxietoxi)ciclopentano-1,2-diol y a sus productos intermedios
EP2361242B1 (de) 2008-10-17 2018-08-01 Oryzon Genomics, S.A. Oxidaseinhibitoren und deren verwendung
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
EP2305376A1 (de) 2009-09-23 2011-04-06 Lonza Ltd. Prozess und Katalysator zur katalytischen Hydrierung von aromatischen und heteroaromatischen Nitroverbindungen
MX338041B (es) 2009-09-25 2016-03-30 Oryzon Genomics Sa Inhibidores de demetilasa-1 especificos de lisina y su uso.
EP2486002B1 (de) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituierte heteroaryl- und arylcyclopropylaminacetamide und ihre verwendung
CA2781182A1 (en) 2009-12-03 2011-06-09 Astrazeneca Ab Co - crystals of a triazolo [4,5 - d] pyrimidine platelet aggregation inhibitor
EA026094B1 (ru) 2009-12-23 2017-03-31 Рациофарм Гмбх Твердая лекарственная форма тикагрелора
CA2788072A1 (en) 2010-02-16 2011-08-25 Actavis Group Ptc Ehf Improved processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
US9186337B2 (en) 2010-02-24 2015-11-17 Oryzon Genomics S.A. Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
KR101794020B1 (ko) 2010-04-19 2017-11-06 오리존 지노믹스 에스.에이. 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도
EP2560939A2 (de) 2010-04-20 2013-02-27 Actavis Group Ptc Ehf Neues verfahren zur herstellung von phenylcyclopropylamin-derivaten mithilfe neuer zwischenprodukte
RU2013103794A (ru) 2010-06-30 2014-08-10 Актавис Груп Птс Ехф Новые способы получения производных фенилциклопропиламина и их применение для получения тикагрелора
US9181198B2 (en) 2010-07-29 2015-11-10 Oryzon Genomics S.A. Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
WO2012013727A1 (en) * 2010-07-29 2012-02-02 Oryzon Genomics S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012063126A2 (en) 2010-11-09 2012-05-18 Actavis Group Ptc Ehf Improved processes for preparing pure (3ar,4s,6r,6as)-6-amino-2,2-dimethyltetrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol and its key starting material
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
MX2013007115A (es) 2010-12-20 2014-02-10 Actavis Group Ptc Ehf Procesos novedosos para preparar derivados de triazolo[4, 5 - d] pirimidina e intermediarios de los mismos.
EP2712315B1 (de) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysindemethylase-hemmer für myeloproliferative erkrankungen
CN102731510B (zh) * 2011-04-07 2015-12-16 博瑞生物医药（苏州）股份有限公司 替卡格雷的衍生物、制备方法及其药物用途
KR20140028011A (ko) 2011-06-01 2014-03-07 아스트라제네카 아베 신규한 티카그렐러 공결정
US20140206867A1 (en) 2011-06-15 2014-07-24 Actavis Group Ptc Ehf Process for Preparing Cyclopentylamine Derivatives and Intermediates Thereof
CN102924457A (zh) * 2011-08-12 2013-02-13 上海恒瑞医药有限公司 ***并嘧啶类衍生物、其制备方法及其用途
CN107266345B (zh) 2011-10-20 2021-08-17 奥瑞泽恩基因组学股份有限公司 作为lsd1抑制剂的(杂)芳基环丙胺化合物
RS58475B1 (sr) 2011-10-20 2019-04-30 Oryzon Genomics Sa Jedinjenja (hetero)aril ciklopropilamina kao lsd1 inhibitori
WO2013060837A1 (en) * 2011-10-27 2013-05-02 Lek Pharmaceuticals D.D. Synthesis of triazolopyrimidine compounds
EP2589587A1 (de) 2011-11-04 2013-05-08 Chemo Ibérica, S.A. Synthese aus stickstoffsubstituierten Cyclopropanen
BR112014013085A2 (pt) 2011-11-30 2017-06-13 Actavis Group Ptc Ehf forma cristalina do ticagrelor, processo para a preparação da forma cristalina do ticagrelor, composição farmacêutica e processo para preparar uma composição farmacêutica
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
WO2013150495A2 (en) 2012-04-05 2013-10-10 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
CN102675321B (zh) * 2012-05-11 2014-12-10 上海皓元化学科技有限公司 一种替卡格雷的制备方法
CN103626743B (zh) * 2012-08-23 2018-06-08 广东东阳光药业有限公司 替卡格雷的新型中间体及其制备方法
CZ2012705A3 (cs) 2012-10-16 2014-04-23 Zentiva, K.S. Pevná orální farmaceutická formulace obsahující ticagrelor
WO2014083139A1 (en) 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Novel amorphous form of ticagrelor
CN103965198A (zh) * 2013-02-05 2014-08-06 郝聪梅 替卡格雷的中间体及其制备方法以及利用该中间体制备替卡格雷的方法
CN103183679A (zh) * 2013-03-20 2013-07-03 西藏海思科药业集团股份有限公司 抗凝血化合物及其应用
CN107573333B (zh) * 2013-04-10 2019-10-18 江苏恒瑞医药股份有限公司 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
EA201501164A1 (ru) 2013-05-29 2016-08-31 Рациофарм Гмбх Твердая фармацевтическая лекарственная форма
WO2014206187A1 (zh) 2013-06-24 2014-12-31 苏州明锐医药科技有限公司 替卡格雷及其中间体的制备方法
CN103588751B (zh) * 2013-11-07 2014-12-17 苏州明锐医药科技有限公司 替格瑞洛中间体的制备方法
WO2015162630A1 (en) 2014-04-25 2015-10-29 Anlon Chemical Research Organization Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis.
US10011605B2 (en) 2014-06-18 2018-07-03 Flamma Spa Process for the preparation of triazolo[4,5-D] pyrimidine cyclopentane compounds
CN105272985B (zh) * 2014-06-24 2017-11-21 珠海联邦制药股份有限公司 ***并[4,5‑d]嘧啶化合物及其合成方法、用途、组合物
US9982061B2 (en) 2014-10-01 2018-05-29 Medimmune Limited Antibodies to ticagrelor and methods of use
WO2016116942A1 (en) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
CN105985346B (zh) * 2015-03-06 2019-10-18 苏州朗科生物技术股份有限公司 一种新的替格瑞洛化合物制备方法及其中间体化合物
TR201601835A2 (tr) 2016-02-12 2017-08-21 Ali Raif Ilac Sanayi Ve Ticaret Anonim Sirketi Ti̇kagrelor i̇çeren formülasyonlar i̇çi̇n üreti̇m yöntemi̇
US9840481B2 (en) 2016-03-22 2017-12-12 Merck Sharp & Dohme Corp. Allosteric modulators of nicotinic acetylcholine receptors
WO2018167447A1 (en) 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants
CN107141298A (zh) * 2017-07-24 2017-09-08 苏州信恩医药科技有限公司 一种替格瑞洛的合成方法
TWI641327B (zh) * 2017-09-30 2018-11-21 双邦實業股份有限公司 Socks that are comfortable and comfortable to wear
EP3527571A1 (de) * 2018-02-14 2019-08-21 Université de Liège Pyrimidinderivate zur vorbeugung und behandlung einer bakteriellen infektion
WO2023213198A1 (zh) * 2022-05-04 2023-11-09 华东师范大学 芳香稠环化合物作为trek-1激活剂的用途、包含其的药物组合物、镇痛剂
CN114805367B (zh) * 2022-05-24 2023-04-07 郑州大学 一种三氮唑并嘧啶类衍生物及其制备方法和应用
CN115710275B (zh) * 2022-11-21 2024-02-02 河南中医药大学 一种嘧啶-tcp类化合物、制备方法和医药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742064A (en) * 1985-09-10 1988-05-03 Regents Of The University Of Minnesota Antiviral carbocyclic analogs of xylofuranosylpurines
GB8826205D0 (en) * 1988-11-09 1988-12-14 Wellcome Found Heterocyclic compounds
DE3924424A1 (de) * 1989-07-24 1991-01-31 Boehringer Mannheim Gmbh Nucleosid-derivate, verfahren zu deren herstellung, deren verwendung als arzneimittel sowie deren verwendung bei der nucleinsaeure-sequenzierung
EP0840740B1 (de) * 1995-07-11 2002-05-02 AstraZeneca AB Inhibitoren der plättchenaggregation
WO1998028300A1 (en) * 1996-12-20 1998-07-02 Astra Pharmaceuticals Ltd. Triazolo[4,5-d]pyrimidinyl derivatives and their use as medicaments

Also Published As

Publication number Publication date
KR100535837B1 (ko) 2006-01-12
EG24412A (en) 2009-05-25
CN1270590A (zh) 2000-10-18
EP0996621A1 (de) 2000-05-03
HK1026421A1 (en) 2000-12-15
DE69818668T2 (de) 2004-08-12
NO20000312D0 (no) 2000-01-21
PL200325B1 (pl) 2008-12-31
TR200000197T2 (tr) 2000-06-21
RU2225407C2 (ru) 2004-03-10
HUP0004333A2 (hu) 2001-04-28
WO1999005143A1 (en) 1999-02-04
TW530058B (en) 2003-05-01
CZ302629B6 (cs) 2011-08-10
EP0996621B1 (de) 2003-10-01
UA66801C2 (uk) 2004-06-15
BR9810802B1 (pt) 2010-10-19
CN1154650C (zh) 2004-06-23
CZ2000233A3 (cs) 2000-07-12
PT996621E (pt) 2004-02-27
IS2236B (is) 2007-05-15
NO20000312L (no) 2000-03-21
DE69818668D1 (de) 2003-11-06
EE04193B1 (et) 2003-12-15
AR077553A2 (es) 2011-09-07
BR9810802A (pt) 2000-09-12
HUP0004333A3 (en) 2001-11-28
SK188199A3 (en) 2000-10-09
ES2207846T3 (es) 2004-06-01
SA98190487B1 (ar) 2006-08-20
CA2296665A1 (en) 1999-02-04
DK0996621T3 (da) 2004-02-02
KR20010022083A (ko) 2001-03-15
AR017014A1 (es) 2001-08-22
PL338516A1 (en) 2000-11-06
IS5354A (is) 2000-01-20
SK284199B6 (sk) 2004-10-05
HU230074B1 (hu) 2015-06-29
CA2296665C (en) 2008-06-10
AU8370698A (en) 1999-02-16
EE200000044A (et) 2000-10-16
MY123196A (en) 2006-05-31
NO315854B1 (no) 2003-11-03
JP4187406B2 (ja) 2008-11-26
AU745381B2 (en) 2002-03-21
IL133959A0 (en) 2001-04-30
IL133959A (en) 2007-10-31
KR20050084540A (ko) 2005-08-26
NZ502381A (en) 2001-12-21
JP2001510842A (ja) 2001-08-07

Similar Documents

Publication Publication Date Title
ATE251161T1 (de) Triazolo(4,5-d)pyrimidin-derivate als antithrombotische mittel
ATE261970T1 (de) Triazolo(4,5-d)pyrimidin-derivate
PT891978E (pt) Derivados de 5h-tiazolo (3,2-a) pirimidina
IS2461B (is) Pýrróló [2,3-dl]pýrimídín efnasambönd
ATE284404T1 (de) Pyrazolo(4,3-d)pyrimidinderivate
NO20006453L (no) Pyrrolo(2,3-d)pyrimidinforbindelser
NO20022738D0 (no) Pyrrolo(2,3-d)pyrimidinforbindelser
ATE219490T1 (de) Indazoleamid-verbindungen als serotoninergene mittel
NO20004089D0 (no) Nye triazolo(4,5-d)pyrimidinforbindelser
DK1210349T3 (da) Pyrazolo[4,3-d]pyrimidiner
NO995033D0 (no) 6,7-disubstituerte-4-aminopyrido[2,3-D]pyrimidinforbindelser
PT1010699E (pt) Derivados de 3-oxadiazolil-1,6-naftiridina-2(h)-ona substituido em 5

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0996621

Country of ref document: EP